Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(71.4%)
Phase 2
2(28.6%)
7Total
Phase 1(5)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07192211Phase 2Not Yet Recruiting

Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG

Role: lead

NCT04873752Phase 1Completed

A Study to Investigate the Safety and Efficacy of UC-MSCs in Pediatric Patients With Cerebral Palsy

Role: lead

NCT04522986Phase 1Completed

An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection

Role: lead

NCT04888949Phase 2Completed

A Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection (COVID-19)

Role: lead

NCT03472742Completed

An Follow-Up Study of Liver Cirrhosis

Role: lead

NCT03254758Phase 1Completed

A Study of ADR-001 in Patients With Liver Cirrhosis

Role: lead

NCT04342325Phase 1Completed

The Clinical Trial of ADR-001 for IgA Nephropathy

Role: collaborator

NCT04695522Phase 1Unknown

ADR-002K for Patients With Ischemic Cardiomyopathy Who Undergo Coronary Artery Bypass Surgery

Role: collaborator

All 8 trials loaded